NIH Hands Patent for Brain-Protecting Drug Tech to Startup
Published Date: 5/16/2025
Notice
Summary
The National Center for Advancing Translational Sciences plans to give Neurala Bio, Inc. an exclusive license to use new inventions related to c-Abl tyrosine kinase inhibitors, which could help develop important medicines. This means Neurala gets special rights to make and use these inventions, possibly speeding up drug research and development. The deal affects researchers, companies, and patients waiting for better treatments, with no immediate cost changes announced.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Exclusive Drug Patent License to Neurala
The National Center for Advancing Translational Sciences plans to give Neurala Bio, Inc. an exclusive patent license to inventions for c-Abl tyrosine kinase inhibitor compounds and their use. This could help speed up drug research and development and affect researchers, companies, and patients, and the notice states there are no immediate cost changes announced.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12244 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide funding for health research projects. Scientists and researchers applying for grants should note these dates as they impact which projects get money.
2026-12116 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important grant applications. These meetings protect private info and trade secrets while helping fund research on mice, drug development, and primate centers. Scientists and research groups applying for grants should watch for these dates as they impact funding decisions.
2026-12106 — Submission for OMB Review; 30-Day Comment Request; NIH Extramural Harassment Web Form (Office of the Director, Office of Extramural Research)
The NIH wants to keep their Extramural Harassment Web Form active so people working with NIH grants can safely report harassment. They’re asking the public to share thoughts by July 16, 2026, but no changes or costs are involved—just a smooth continuation. This helps keep NIH’s research community respectful and safe!
2026-12070 — Government Owned Inventions Available for License: Establishment and Characterization of the A1847 Human Ovarian Carcinoma Line
The National Cancer Institute is offering a special ovarian cancer cell line called A1847 for researchers to license and use. This cell line helps scientists study how ovarian cancer grows and find better treatments, especially for tough cases linked to BRCA1 gene problems. If you’re into cancer research, this is your chance to get a powerful tool starting now, with no big costs for licensing.
2026-11892 — Proposed Collection; 60-Day Comment Request; Specimen Resource Locator (National Cancer Institute)
The National Cancer Institute wants your thoughts on a new way to track and locate cancer research samples through their Specimen Resource Locator. This affects researchers and labs who use these samples, aiming to make finding and sharing easier without adding extra costs or delays. You’ve got 60 days to share your feedback and help shape this helpful tool!
2026-11390 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings in July 2026 to review and decide on important research grant applications. These meetings protect private info and trade secrets while helping decide who gets funding to advance science. Researchers applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
Previous / Next Documents
Previous: 2025-08740 — Robert D. Willis Power Rate
Southwestern Power Administration plans to raise the Robert D. Willis hydropower rates by 28.6%, boosting yearly revenue from about $1.28 million to $1.65 million starting August 1, 2025, through September 30, 2027. This change affects customers using power from this project and gives everyone a chance to review and comment before it kicks in. Get ready to check out the details and share your thoughts soon!
Next: 2025-08744 — National Institute of Arthritis and Musculoskeletal and Skin Diseases; Notice of Closed Meeting
The National Institute of Arthritis and Musculoskeletal and Skin Diseases is holding a private meeting on August 15, 2025, to review grant applications. This closed session protects sensitive info like personal details and trade secrets. Researchers applying for funding should note this important step in the grant process, but no new rules or money changes are announced.